First Patient Dosed in Ph 2a Clinical Trial of GFH009 in AML
“We are excited to advance GFH009 to the next phase of clinical development, which we believe holds great promise for patients who continue to suffer with advanced and difficult to treat AML,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “As far as we know, GFH009 is the only CDK9 inhibitor in development that, as a single agent, has shown such unique and very encouraging clinical data which is the reason our hematology experts see high promise in this Phase 2a study. Treatment of the first patient in this study represents successful completion of one of several near-term potential value enhancing milestones.”
Share:
More News
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: “We are building a broad pipeline of ADCs addressing novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class
“The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase 3 CREST results are potentially practice-changing, representing the first advance in therapy for BCG-naïve, high-risk, non-muscle invasive cancer in over 30 years,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “These
“Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options,” commented Doug Warner, Chief Medical Officer of TYRA. “We look forward to leveraging Erik’s impressive background to guide our development plans in NMIBC. We expect
“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance
